CHAPEL HILL, N.C., June 17, 2016 /PRNewswire/ — Despite all the pressures facing the pharmaceutical industry, product launches continue across multiple therapeutic areas – including new drugs for diabetes. For crowded therapeutic areas like diabetes, the launch landscape is a particularly difficult one that requires sound strategies and execution to successfully navigate.
In a wide-ranging research project that explores the pivotal success factors and failure points facing new product launches, Best Practices, LLC established a critical core set of factors that can make or break a market entry for metabolic products as well as other types of therapies.
The report, Success Factors and Failure Points in Metabolic Product Launches, examines key launch issues and offers launch leaders two perspectives: a metabolic/diabetes segment and a total benchmark class segment. The study presents a framework for launch success: the ability to differentiate, a defined target patient population, investment in launch activities, engagement of thought leaders, education of key stakeholders, demonstration of value, utilization of new technologies and avoidance of launch pitfalls.
In addition to delivering qualitative and quantitative insights on each aspect of this launch framework, the report presents launch leaders’ perspectives on the current and future risk levels for an array of pitfall factors that can affect a launch.
Best Practices, LLC used both field surveys and interviews to complete this study. In all, 44 managers and executives at 38 leading bio-pharma companies participated in the survey. In-depth interviews were conducted with leaders from six organizations who have decades of experience with pharma launches.
Topics covered in this study include:
To download a complimentary study excerpt, go to: http://www.best-in-class.com/rr1432.htm.
For more information on this study or other recent primary research studies, contact us at 919.403.0251 or at email@example.com.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC’s clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations. Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.
SOURCE Best Practices, LLC